NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom investors who were adversely affected by alleged securities fraud between January 8, 2024 and September 17, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission- ...

Group 1: Bank of Nova Scotia - The Bank of Nova Scotia is considered a "very good" company by Jim Cramer, who highlighted its better-than-expected fourth-quarter results [1] - Bank of Nova Scotia shares gained 0.4% to close at $72.92 [6] Group 2: Strategy Inc - Bernstein analyst Gautam Chhugani maintained an Outperform rating for Strategy Inc but lowered the price target from $600 to $450 [2] - Strategy shares fell 0.7% to settle at $183.30 [6] Group 3: AST SpaceMobile, Inc. - Cramer described AST SpaceMobile as speculative, indicating potential for significant losses [2] - AST SpaceMobile shares rose 7.2% to settle at $84.75 [6] - The company announced the addition of two new manufacturing sites in Texas and Florida [2] Group 4: DexCom, Inc. - Cramer expressed a lack of interest in owning DexCom, despite Citigroup analyst Joanne Wuensch maintaining a Buy rating and raising the price target from $75 to $77 [3] - Dexcom shares gained 2% to close at $68.94 [6] Group 5: NRG Energy - Cramer recommended buying NRG Energy, citing its nuclear component and strong management [3] - UBS analyst William Appicelli initiated coverage on NRG Energy with a Buy rating and a price target of $211 [3] - NRG Energy shares rose 1.5% to settle at $170.64 [6] Group 6: MercadoLibre, Inc. - Cramer endorsed MercadoLibre as a buy, calling it "such a good company" [4] - BTIG analyst Marvin Fong reiterated a Buy rating on MercadoLibre with a price target of $2,750 [4] - MercadoLibre shares gained 2.5% to close at $2,019.81 [6]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit alleging that the company made misleading statements about its glucose monitoring products, the G6 and G7, which may have health risks for users [1][3]. Group 1: Allegations Against DexCom - The complaint alleges that DexCom made unauthorized design changes to the G6 and G7 glucose monitoring products, which were not approved by the U.S. Food and Drug Administration [3]. - These design changes reportedly made the G6 and G7 less reliable than previous versions, posing a material health risk to users who depend on these devices for accurate glucose readings [3]. - The enhancements claimed for the G7, including its reliability, accuracy, and functionality, were allegedly overstated by the defendants [3]. - The true scope and severity of the issues and health risks associated with the altered G7 devices were downplayed by the defendants [3]. - As a result of these actions, DexCom faced increased risks of regulatory scrutiny and potential legal, reputational, and financial harm [3]. - The public statements made by the defendants were claimed to be materially false and misleading throughout the relevant period [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as January 8, 2024, to September 17, 2025 [3]. - Shareholders are encouraged to register for the class action by December 26, 2025, to be eligible for potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [5]. - The firm aims to ensure that companies engage in responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities between July 26, 2024, and September 17, 2025, of the December 29, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought DexCom securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1] - To join the class action, investors can visit the provided link or contact Phillip Kim, Esq. for more information [2][5] - A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation, and interested parties must file their motion by December 29, 2025 [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3] Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 continuous glucose monitoring systems, which rendered them less reliable and posed health risks to users [4] - Defendants allegedly overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues and health risks associated with them [4] - The allegations suggest that these misrepresentations subjected DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [4]

Core Viewpoint - Holzer & Holzer, LLC is reminding investors of deadlines to seek lead plaintiff status in several class action lawsuits against companies including MoonLake Immunotherapeutics, DexCom, and Synopsys, alleging misleading statements and failure to disclose material facts during specified periods [1][2][3]. Group 1: MoonLake Immunotherapeutics (MLTX) - A class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging that the company made materially false and/or misleading statements regarding SLK's superiority to monoclonal antibodies between March 10, 2024, and September 29, 2025 [1]. - Investors who purchased shares during this period and suffered significant losses are encouraged to discuss their legal rights [1]. Group 2: DexCom, Inc. (DXCM) - A class action lawsuit has been filed against DexCom, alleging that the company made materially false and/or misleading statements regarding design changes to its G6 and G7 products between January 8, 2024, and September 17, 2025 [2]. - Investors who purchased shares during this period and suffered significant losses are encouraged to discuss their legal rights [2]. Group 3: Synopsys, Inc. (SNPS) - A class action lawsuit has been filed against Synopsys, alleging that the company made materially false and/or misleading statements regarding the economics of its Design IP business between December 4, 2024, and September 9, 2025 [3]. - Investors who purchased shares during this period and suffered significant losses are encouraged to discuss their legal rights [3]. Group 4: Holzer & Holzer, LLC - Holzer & Holzer, LLC is recognized as a top-rated securities litigation law firm and has been involved in recovering hundreds of millions of dollars for shareholders affected by fraud and corporate misconduct since its founding in 2000 [4]. - The firm is dedicated to representing shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation [4].

Core Points - Class actions have been initiated on behalf of stockholders of DexCom, Inc. and CarMax, Inc. with specific deadlines for investors to petition the court to serve as lead plaintiff [1] DexCom, Inc. (NASDAQ:DXCM) - The class period for DexCom is from January 8, 2024, to September 17, 2025, with a lead plaintiff deadline of December 26, 2025 [6] - The complaint alleges that DexCom made materially false and misleading statements regarding its business and compliance policies, including unauthorized design changes to the G6 and G7 devices that compromised their reliability and posed health risks to users [6] - The lawsuit claims that these misstatements subjected DexCom to increased regulatory scrutiny and potential legal and financial harm [6] CarMax, Inc. (NYSE:KMX) - The class period for CarMax is from June 20, 2025, to September 24, 2025, with a lead plaintiff deadline of January 2, 2026 [6] - The lawsuit alleges that CarMax's defendants overstated growth prospects, attributing earlier growth to temporary factors related to customer behavior influenced by tariff speculation [6] - As a result, the statements made by CarMax's defendants regarding the company's business and operations were deemed materially false and misleading [6]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit alleging that the company made misleading statements about its glucose monitoring products, G6 and G7, which may have health risks for users [1][3]. Group 1: Allegations Against DexCom - The complaint alleges that DexCom made unauthorized design changes to the G6 and G7 glucose monitoring products, which were not approved by the U.S. Food and Drug Administration [3]. - These design changes reportedly made the G6 and G7 less reliable than previous versions, posing a material health risk to users who depend on these devices for accurate glucose readings [3]. - The enhancements claimed for the G7, including its reliability and accuracy, were allegedly overstated, and the company downplayed the severity of the issues related to the G7 devices [3]. Group 2: Legal and Financial Implications - The allegations suggest that DexCom is facing increased regulatory scrutiny and potential enforcement actions, which could lead to significant legal, reputational, and financial harm [3]. - The public statements made by DexCom during the class period are claimed to be materially false and misleading, impacting investor trust and stock performance [3]. Group 3: Class Action Participation - Shareholders who purchased shares of DXCM between January 8, 2024, and September 17, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for December 26, 2025 [4]. - Once registered, shareholders will receive updates on the case through a portfolio monitoring software, with no cost or obligation to participate [4].

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as we ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the DexCom securities is from July 26, 2024, to September 17, 2025, inclusive [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - The deadline to move the Court to serve as lead plaintiff is December 29, 2025 [2] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability [4] - It is claimed that these changes presented a material health risk to users relying on the devices for accurate glucose readings [4] - The defendants allegedly downplayed the severity of the issues, leading to increased regulatory scrutiny and potential legal repercussions for DexCom [4]

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. who suffered losses exceeding $100,000 during the specified class period to seek legal counsel before the December 29, 2025 deadline for lead plaintiff applications [1][2]. Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be eligible for compensation without any upfront costs through a contingency fee arrangement [2]. - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - The defendants are accused of making misleading statements regarding the reliability and functionality of the G6 and G7 devices, which led to increased regulatory scrutiny and potential financial harm to the company [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - To participate in the class action, investors can visit the provided link or contact the firm directly for more information [3][6].